Novavax Stock Probability Of Bankruptcy
NVV1 Stock | EUR 8.20 0.28 3.54% |
Novavax |
Novavax Company chance of financial distress Analysis
Novavax's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Novavax Probability Of Bankruptcy | Over 58% |
Most of Novavax's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Novavax probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Novavax odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Novavax financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition |
Based on the latest financial disclosure, Novavax has a Probability Of Bankruptcy of 58%. This is 33.98% higher than that of the Healthcare sector and 5.76% higher than that of the Biotechnology industry. The probability of bankruptcy for all Germany stocks is 45.62% lower than that of the firm.
Novavax Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.Novavax is currently under evaluation in probability of bankruptcy category among its peers.
Novavax Fundamentals
Return On Equity | -8.98 | |||
Return On Asset | -0.32 | |||
Profit Margin | (0.72) % | |||
Operating Margin | (0.66) % | |||
Current Valuation | 484 M | |||
Shares Outstanding | 85 M | |||
Shares Owned By Insiders | 0.45 % | |||
Shares Owned By Institutions | 62.33 % | |||
Price To Book | 72.32 X | |||
Price To Sales | 0.45 X | |||
Revenue | 1.15 B | |||
Gross Profit | (1.39 B) | |||
EBITDA | (1.68 B) | |||
Net Income | (1.74 B) | |||
Cash And Equivalents | 1.57 B | |||
Cash Per Share | 20.11 X | |||
Total Debt | 323.46 M | |||
Debt To Equity | 8.24 % | |||
Current Ratio | 1.04 X | |||
Book Value Per Share | (7.21) X | |||
Cash Flow From Operations | 322.95 M | |||
Earnings Per Share | (15.18) X | |||
Target Price | 264.2 | |||
Number Of Employees | 1.54 K | |||
Beta | 1.72 | |||
Market Capitalization | 727.55 M | |||
Total Asset | 2.58 B | |||
Z Score | 1.2 | |||
Net Asset | 2.58 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.